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BACKGROUND: Integrating quality-of-life (QOL) outcomes into clinics may assist providers in identifying and responding to problems
experienced by cancer survivors. To date, however, patient-reported outcomes (PROs) such as QOL are used infrequently to guide
care. We integrated QOL assessments into a prostate cancer survivorship clinic and compared recovery and satisfaction among men
managed in the survivorship clinic with those followed with more routine care. METHODS: We conducted a before-after study com-
paring 235 men treated surgically for prostate cancer who received routine follow-up care with 102 men managed in a survivorship
clinic characterized by point-of-care QOL reporting and integration of QOL scores (EPIC) following radical prostatectomy. We then
assessed baseline and postprostatectomy QOL at 6 and 12 months, as well as patient satisfaction, and compared outcomes between
groups. RESULTS: Although baseline QOL was comparable, scores were generally higher among the survivorship group at 6 months
and 1 year compared with those followed with routine care. In particular, sexual function scores were significantly higher among
patients managed in the survivorship clinic (52.2 vs 33.6 at 1 year, P< .01). Satisfaction scores were consistently higher in the survivor-
ship clinic group compared with the routine-care group (all P<.05). CONCLUSIONS: Patient QOL and satisfaction were higher among
men managed in a survivorship program, suggesting that disease-specific survivorship clinics that integrate QOL reporting into care
pathways may yield better outcomes compared with less tailored approaches to patient care following cancer therapy. Cancer
2015;121:1484-91. VC 2014 American Cancer Society.
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INTRODUCTION
Although most men treated for localized prostate cancer experience favorable cancer outcomes, treatment is often associ-
ated with lasting functional and quality-of-life (QOL) impairments. For example, men treated surgically (prostatectomy)
face a 10%-15% risk of problematic urinary incontinence and greater than 50% risk of erectile dysfunction.1,2 Radiation
therapy is associated with similar QOL deficits, including sexual dysfunction, exacerbation of obstructive urinary symp-
toms, and bothersome bowel symptoms.3-5 As a result, there has been long-standing interest in assessing quality-of-life
outcomes among this patient population. However, prior efforts in this area have been primarily research oriented, focus-
ing on instrument development, measurement and assessment of treatment-related consequences. Relatively little work
has focused on integrating or translating QOL outcomes into clinical settings to guide patient care, in part because of a
lack of available point-of-care tools to collect, score, and interpret patient-reported outcomes during clinic visits. Other
barriers limiting the use of QOL in clinical care include logistical issues, such as lack of provider time to track functional
outcomes or use them to guide interventions. As a result, treatment-related impairments and health problems may go
unrecognized or underassessed.
Integrating QOL measurement into clinical settings may positively impact patient care, particularly in preference-
sensitive conditions that involve trade-offs in potential complications and health states. These objectives are also concord-
ant with Institute of Medicine recommendations to incorporate systematically developed assessment tools into routine
clinical care to better identify the late effects of cancer and its treatment.6 The use of computer-based, interactive surveys
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in the clinic, for example, has the potential to improve
provider and patient awareness of treatment-related
symptoms and impairments in a timely manner. Previous
research has demonstrated a number of benefits of using
computerized QOL assessment systems in the clinical set-
ting.7,8 Implementing QOL assessment in clinical prac-
tice has been shown to increase physician awareness of
QOL issues and improve patient-physician communica-
tion during consultation9,10 and has led to better out-
comes in other health domains, such as patient well-being
and satisfaction.11,12
Despite these encouraging findings, point-of-care
QOL assessment is not yet widespread. In addition to
practical challenges associated with translating QOL in-
formation into clinical settings, the extent to which incor-
porating quantitative PROs into routine clinical care
improves patient care and outcome is not fully known. In
this context, we hypothesized that using PROs to guide
survivorship care improves clinical outcomes and sought
to further study this area by integrating QOL assessments
into the routine follow-up care of prostate cancer survi-
vors and adapting survivorship care to patient-reported
outcomes QOL assessment.
MATERIALS AND METHODS
Study Design and Cohort
A total of 337 men treated surgically (radical prostatec-
tomy) for localized prostate cancer (stage and Gleason in-
formation) were included in the study. A controlled
before-after observational cohort study design was used
because of practical limitations in performing a random-
ized controlled trial, such as contamination issues associ-
ated with randomizing patients to a clinic-level
intervention at a single institution and complexity-related
challenges associated with clustered or group randomiza-
tion across multiple clinics and/or institutions. Quasiex-
perimental approaches, such as before-after study designs,
are often used in settings in which randomization is not
practical or possible.13,14 The “before” group consisted of
235 men treated with radical prostatectomy at the Univer-
sity of Michigan between April 2003 and March 2006
who were followed with routine clinical follow-up care.
The “after” group consisted of 102 men treated surgically
at the University of Michigan between 2008 and 2010.
Study patients in the ‘after” group were followed in a
dedicated prostate cancer survivorship program that
incorporated point-of-care QOL assessment into follow-
up clinic visits to guide care, and dedicated nursing and
sexual health therapist consultations to address detected
incontinence and sexual dysfunction following surgery.
Survey panels were administered and collected at regular
intervals (baseline, and 6, 12, and 24 months posttreat-
ment) in both groups.
Surveys and Study Outcome Measures
Aspects of functional recovery (urinary continence and
erectile dysfunction), and corresponding disease-specific
quality of life were assessed using the Expanded Prostate
Cancer Index Composite (EPIC).15 EPIC is a reliable and
valid health scale consisting of 26 items covering 5
domains (urinary continence, urinary irritation, sexual
function, bowel function, and vitality) and is scored on a
0-100 summary scale, with higher scores correspond to
higher health states. Patient satisfaction was assessed using
a cancer-specific adaptation of the Service Satisfaction
Scale (SCa).16,17 The SCa consists of 16 items and meas-
ures several aspects of satisfaction, including satisfaction
with outcome, provider manner and skill, health informa-
tion, and access. Responses are scored and converted to a
0-100 scale, with higher scores indicating higher levels of
patient satisfaction. Surveys were self-completed by study
participants prior to surgery (baseline) and at regular
intervals (6, 12, and 24 months in follow-up) after sur-
gery. “Before”-group patients completed surveys in paper-
pencil format, whereas “after”-group patients completed
electronic surveys to facilitate point-of-care scoring.
Changes in quality-of-life scores served as the primary
outcome, and satisfaction scores served as the secondary
study outcome. In addition to absolute scores, time to
functional recovery, defined as the time required for scores
to return to 75% of baseline, was also examined as an out-
come measure.18
Study Setting
All study patients were treated at a high-volume tertiary
referral academic cancer center. “Before”-group patients
were managed through standard clinical evaluation and
management pathways without PRO integration or use of
QOL assessment to guide their subsequent care. In con-
trast, patients in the “after” group were followed through
a dedicated prostate cancer survivorship clinic designed to
objectively identify treatment-related dysfunction and
deficits through an electronic, point-of-care QOL assess-
ment system. The survivorship program was implemented
in 2007 and consisted of 2 distinguishing features com-
pared with the routine care provided through most urol-
ogy clinics: 1) integration of patient-reported QOL
outcome reporting at the point of care; 2) protocol-driven
referral to dedicated nursing, pelvic floor physical therapy
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and sexual health therapist consultations during follow-up
visits tailored to reported QOL outcomes. Through this
system, QOL surveys were administered, scored, and out-
put into dashboard reports for patient and provider review
during clinic visits. Dashboards included prior QOL
scores if available, calculated minimally important differ-
ences,19 and displayed score trajectories over time to pro-
vide objective patient-specific outcomes and changes
(increased or declines) in QOL scores. Dashboards were
available for providers and patient review during clinic
visits with the intent that they be used as a clinical tool to
identify areas of concern and prompt referral to rehabilita-
tion services, such as sex therapists, pelvic floor rehabilita-
tion physical therapists, or an erectile dysfunction
specialist (Fig. 1, Addendum).
Statistical Analysis
EPIC scores in “before” and “after” groups were com-
pared using the Wilcoxon rank-sum test for each time.
Adjusted generalized linear models (GLMs) were then
used to assess the independent effect of management in
the survivorship clinic (“after” group) compared with
usual care (“before” group). Variables included in the
models were group (“after” vs “before”), age, race (white,
black, other), BMI (obese, overweight, normal), Gleason
score (6, 7, 8-10), stage (T3 vs T2), nerve sparing (yes vs
no), and surgical approach (robotic/laparoscopic vs
open), as well as patient history of diabetes, hypertension,
prior myocardial infarction, or other cancer. All tests were
performed with a 2-sided significance level set at .05. This
analysis focused on 1-year cross-sectional scores. Func-
tional recovery, defined as recovery of QOL scores to at
least 75% of the baseline level for each subject, was also
examined and compared between “before” and “after”
groups.18 Differences between the groups in patient satis-
faction were then assessed at 6 and 12 months using the
Wilcoxon rank-sum test. Differences between the
“before” and “after” groups in clinical and demographic
variables (eg, changes in stage and Gleason score, and dif-
ferences in percentage of cases managed with nerve-
sparing and/or robot-assisted laparoscopic prostatectomy)
were explicitly examined and included in models to
account and adjust for potential secular trends given the
before-after study design. Sample-size estimates using 0.5
standard deviations of a QOL measure as a threshold to
determine clinically meaningful differences between
groups estimated that a sample of 100 patients per group
(based on the size of the “after” group) would provide 0.9
power at a .05 significance level. All tests were performed
at the 5% significance level (2 sided) using standard statis-
tical software (SAS, 9.4, Cary, NC). The study was
approved and overseen by the University of Michigan
Institutional Review Board.
RESULTS
Clinical and demographic variables are shown in Table 1.
There were no differences in age or race. Although most
men were white in both groups, black men comprised
between 5% and 6% of both the “before”-group and the
“after”-group cohorts. No differences in clinical stage
were noted, although the “after” group was characterized
by slightly lower prostate-specific antigen values (median,
6.1 and 4.7 ng/mL for the “before” and “after” groups,
respectively). Similarly, there were a greater number of
Gleason 6 cases among the “before” group, likely reflect-
ing secular changes in the management of low-risk, early-
stage prostate cancer and stricter treatment criteria among
the “after”-group patients.
Quality-of-life and patient satisfaction scores at 6
months and 1 year are shown in Table 2. Significant dif-
ferences were noted in sexual function and vitality
domains of EPIC at 1 year, favoring the “after” group
(33.6 vs 52.2 for sexual function scores). The “after”
group also consistently demonstrated higher satisfaction
scores across all 4 domains of satisfaction (outcome, serv-
ice, information, and access). For example, the “after”-
Figure 1. Survivorship clinic process schema.
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group scores were 95.8 for satisfaction with outcomes and
93.7 for satisfaction with access compared with 89.0 and
89.5, respectively, in the “before” group.
Figures 2 and 3 display recovery of sexual function
and urinary continence across assessment points and the
proportion of men achieving recovery to 75% of baseline,
respectively. Although both groups started with similar
baseline scores, sexual function scores were higher at 6,
12, and 24 months among those managed through the
survivorship clinic (Fig, 2A), and a greater proportion of
men in the “after” group reached 75% of their baseline
sexual function score (Fig. 3A). Although urinary conti-
nence scores were similar in the groups across all times
(Fig. 2B), a high percentage of patients in the “after”
group achieved recovery of urinary incontinence scores to
75% of baseline scores (Fig. 3B).
Results of the adjusted generalized linear regression
models are shown in Table 3. Although the survivorship
clinic was not associated with better urinary function, the
“after” group was independently associated with higher
sexual function and satisfaction scores. Older age and dia-
betes were also independently associated with decreased
sexual function scores. Other potential confounding fac-
tors, such as disease stage, Gleason score, performance of
nerve sparing, and the use of robot-assisted laparoscopic
prostatectomy, were not significantly associated with out-
comes in the adjusted GLM.
DISCUSSION
A major goal of survivorship research is to identify and
remediate functional disabilities related to cancer and its
treatment. To move these objectives forward, concerted
efforts to integrate assessment tools into routine clinical
care are needed. Using point-of-care PRO QOL assess-
ments and dashboards in a dedicated survivorship clinic,
we found that functional scores, recovery, and satisfaction
improved compared with routine care. Most notably,
postprostatectomy sexual function scores and the likeli-
hood of recovering to within 75% of baseline were signifi-
cantly greater among men in the “after” group than in
those in the “before” group. However, only about half of
men in the “after” group achieved this level of recovery,
indicating that even in survivorship care settings resourced
with dedicated functional recovery personnel and pro-
grams, substantial progress is still needed. Another key
finding in our study was that the survivorship clinic was
independently associated with both sexual recovery and
patient satisfaction. Although there were differences in
group characteristics (eg, Gleason score, use of robot-
assisted laparoscopic approach) that may have contributed
to differences in functional outcomes, those factors were
not significantly associated with better outcomes in
adjusted models, and the survivorship program (“after”
group) remained the primary predictor of better outcomes
in final models. Our results were further bolstered by the
extent to which survivorship care improved patient satis-
faction; men in the “after” group endorsed significantly
higher satisfaction scores across all measured domains
(satisfaction with outcome, access, manner/skill, and in-
formation). These results suggest that dedicated programs
that incorporate PRO into clinical care improve care on a
number of fronts.
To date, research efforts among early-stage prostate
cancer survivors have focused primarily on measuring and
comparing patient-reported QOL outcomes following
local therapy.1,5,20,21 Despite the importance of this
work, there has been little effort to examine if a better
understanding of the consequences that commonly result
from managing early-stage prostate cancer translate into
better recognition and management of functional and
quality-of-life deficits or to improvements in the survivor-
ship experience. A major barrier to achieving this goal has
been the failure to incorporate patient-reported QOL
widely into clinical practice. Nevertheless, using a
computer-based, interactive format has the potential to
TABLE 1. Clinical and Demographic Variables
Between “Before” and “After” Groups
Before After P
n 235 102
Age 59.3 (38.8-76.2) 60.8 (43.4-76.2) .43
BMI 27.9 (19.2-41.1) 28.3 (17.8-39.6) .14
Race .13
White 217 (93.1) 91 (89.2)
Black 13 (5.6) 6 (5.9)
Other 3 (1.3) 5 (4.9)
Comorbidities
Diabetes 22 (9.4) 10 (9.8) .90
Hypertension 86 (36.6) 53 (52.0) .01
CAD/MI 14 (6.0) 3 (2.9) .25
Previous cancer 30 (12.8) 9 (8.8) .30
PSA 6.1 (0.5-51.0) 4.7 (0.6-54.3) <.0001
Gleason score <.0001
6 123 (52.3) 21 (21.0)
7 103 (43.8) 73 (73.0)
8-10 9 (3.8) 6 (6)
Stage .44
Stage 2 194 (84.0) 89 (87.3)
Stage 3 37 (16.0) 13 (12.7)
Nerve sparing 198 (85.7) 86 (84.3) .74
Approach <.0001
Open 140 (59.6) 6 (5.9)
Laparoscopic/robotic 95 (40.4) 96 (94.1)
Abbreviations: BMI, body mass index; CAD, coronary artery disease; MI,
myocardial infarction; PSA, prostate-specific antigen.
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improve provider awareness of patient symptoms and
health impairments at the point-of-care. Previous studies
have shown beneficial effects of using computerized QOL
assessment systems in the clinical setting. Implementing
QOL assessment in clinical practice increases physician
awareness of QOL issues, improves patient-physician
communication, and can help patient well-being.22 For
example, Detmar and colleagues found that quality-of-life
issues were discussed significantly more frequently when
QOL survey results were available during clinic visits and
that physicians were more likely to identify moderate to
severe health problems when incorporating PRO into
their clinical assessments.9 Velikova and colleagues have
shown that point-of-care QOL reports not only broaden
issues discussed during clinic visits and focus physician
evaluations on patient-reported concerns, but also con-
tribute to patient well-being and improve subsequent
QOL.10,12 Similar to our findings, Giesler et al reported
long-term improvement in QOL outcomes among men
treated for localized prostate cancer who participated in a
nurse-driven intervention focused on computer capture
and review of serial QOL assessment following treatment
compared with those who did not.23 Currently, however,
patient-reported outcomes such as quality of life are sel-
dom assessed or integrated in most clinical settings.
The results of our study indicate that clinic-level sys-
tems that collect, report, and integrate quality-of-life
assessments and outcomes into the management of men
treated for early-stage prostate cancer can help to increase
recognition of the functional problems associated with
TABLE 2. Mean QOL and Satisfaction Scores in “Before” and “After” Groups
Baseline 6 Months 1 Year
Before After P Before After P Before After P
Urinary incontinence 94.1 94.5 .70 72.4 74.6 .24 78.9 78.0 .89
Urinary irritation 86.3 88.5 .35 90.7 93.3 .08 92.7 94.9 .34
Sexual function 77.6 71.9 .30 25.3 43.2 <.01 33.6 52.2 <.01
Bowel function 96.0 95.2 .52 95.9 97.8 .07 95.2 96.9 .19
Hormone function 91.3 94.0 <.01 90.1 94.5 .01 90.2 95.1 .03
Satisfaction with outcome 88.2 93.1 <.01 89.0 95.8 <.01
Satisfaction with manner/skill 91.1 95.4 <.01 90.5 97.0 <.01
Satisfaction with information 88.1 94.8 <.01 87.9 96.4 <.01
Satisfaction with access 89.3 93.1 <.01 89.5 93.7 .02
Figure 2. (A) Mean EPIC sexual function scores in “before” and “after” groups. (B) Mean EPIC urinary continence scores in
“before” and “after” groups.
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prostatectomy (eg, incontinence and erectile dysfunc-
tion), direct the evaluation and management of functional
deficits, and improve key patient outcomes, such as func-
tional recovery and patient satisfaction. The success of
such systems hinges not only on point-of-care PRO assess-
ment, but also on the integration of those outcomes into
clinic care through a reporting infrastructure (eg, dash-
boards), and linking PRO assessment to downstream clin-
ical resources that exist within the framework of a
survivorship program, such as dedicated nurses who focus
on reviewing concerns and detected deficits with patients,
physical therapists specializing in pelvic floor rehabilita-
tion, and sex therapists and counselors. In the setting of
the University of Michigan Prostate Cancer Survivorship
Program, patients experienced significant benefits. Not
only were functional QOL scores higher than patients
managed through a dedicated, comprehensive survivor-
ship program, patient satisfaction was consistently higher
across several satisfaction domains, including satisfaction
with outcomes, provider skill, information, and access.
These results likely reflect more responsive, expert, and
timely management facilitated by the availability of PROs
at the point of care. Higher satisfaction scores, moreover,
may reflect better service experiences, in part through
ready access to health information and resources among
men managed trough the survivorship clinic. More
broadly, the results of this study suggest that comprehen-
sive survivorship programs that integrate PRO assess-
ments into the clinical work flow of patient care may
translate to more patient-centered care and better health
outcomes following cancer treatment.
The findings from our study should be interpreted
in the context of several limitations. First, this was a non-
randomized study, so causality between PRO reporting
and the survivorship clinic cannot be directly inferred,
given potential confounding and selection bias inherent
in nonrandomized studies. We used a quasiexperimental
before-after approach largely because of pragmatic con-
cerns related to possible contamination resulting from
randomizing a clinicwide intervention within a single
clinical setting and the inability to implement a larger,
multi-institutional clustered randomization scheme,
given the initial scope of the project. Furthermore, the
before-after study design leveraged existing QOL data
from a relatively contemporaneous cohort of men treated
with prostatectomy. Second, our study was limited to
men treated surgically with radical prostatectomy.
Although early-stage prostate cancer can be treated with
a number of modalities (surgery, external radiation ther-
apy, interstitial brachytherapy, cryotherapy), we chose to
focus on surgery to simplify the study’s implementation
and because data from a surgical “before” group was
readably accessible. Our approach and findings, however,
are likely applicable across treatment modalities. Third,
secular trends in surgical approach represent a possible
source of confounding. As reflected in Table 1, a larger
Figure 3. (A) Recovery to 75% of baseline sexual function
scores in “before” and “after” groups, (B) Recovery to 75% of
baseline urinary function in “before” and “after” groups.
TABLE 3. Multivariable-Adjusted Modeled Differen-
ces in Means for Functional and Satisfaction Scores
Sexual Function
Satisfaction With
Outcome
Variable D in Mean SE P D in Mean SE P
Before group Referent - - Referent - -
After group 19.539 4.145 <.0001 5.985 1.659 .0004
Patient age 20.898 0.273 .001 0.092 0.101 .366
Diabetes Referent - - Referent - -
No diabetes 12.712 5.993 .035 22.988 2.165 .169
Nerve sparing Referent - - Referent - -
Non–nerve sparing 24.117 4.913 .403 20.621 1.878 .741
Robotic/laparoscopic Referent - - Referent - -
Open 1.446 7.950 .856 0.657 2.869 .819
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percentage of men underwent robotic-assisted laparo-
scopic prostatectomy in the “after” group than in the
“before” group. The timeframe of “after”-group accrual
coincided with the introduction and more frequent use
of robotic prostatectomy; however, most evidence com-
paring open with robotic prostatectomy has not demon-
strated a substantial difference in functional outcomes
between the 2 approaches, particularly during the learn-
ing phase of robotic prostatectomy.24-26 Further, the use
of robotic-assisted surgery was not significantly associated
with better QOL scores in our study, suggesting that this
potential confounder did not affect our results signifi-
cantly. Other surgical techniques may have also differed
between groups. For example, the use of anterior ure-
thropexy has been used relatively frequently during
robotic prostatectomy to decrease urethral mobility and
aid in recovery of urinary continence.27 Our findings
uncovered more substantial differences in erectile and
sexual functional outcomes than for continence out-
comes, so the application of such nuanced surgical tech-
niques may not translate to substantial gains in PROs.
The larger effect in sexual recovery may have also resulted
from relatively low rates of urinary incontinence with
current surgical and postoperative care. Men in the
“after” group also reported significantly higher satisfac-
tion, which may correlate directly with more patient-
centered care or may potentially be influenced by more
frequent visits with health care providers. However, the
increase in satisfaction scores across all satisfaction
domains, including satisfaction with outcome supports
the former association. Despite these limitations, the
results of this study provide useful information regarding
the advantage of integrating and responding to PROs in
clinical practice.
Conclusions
Integrating PROs such as QOL into clinical practice
through practical point-of-care systems and responding to
those outcomes through a comprehensive, structured
approach based on dedicated resources improve func-
tional outcomes and are associated with higher patient sat-
isfaction. Although these initial finding support
survivorship models of care to address and manage
treatment-related deficits among cancer survivors, addi-
tional larger-scale studies performed using randomized
approaches are necessary to better define the efficacy of
survivorship care programs.
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